A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Latest Information Update: 17 Nov 2023
At a glance
- Drugs Irinotecan (Primary) ; Temozolomide (Primary) ; Temozolomide (Primary) ; Cyclophosphamide; Dexrazoxane; Doxorubicin; Etoposide; Ifosfamide; Mesna; Vincristine
- Indications Ewing's sarcoma
- Focus Therapeutic Use
- 08 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2023 Planned End Date changed from 1 May 2023 to 1 May 2027.
- 01 Jun 2023 Planned primary completion date changed from 1 May 2023 to 1 May 2027.